Schedule Of Interest Expenses |
Total debt consists of the following as of December 31, 2018 and December 31, 2017:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Subordinated Note Financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Subordinated Note Financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Subordinated Note Financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Subordinated Note Financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Subordinated Note Financing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Helocyte Convertible Note, at fair value 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Helocyte Convertible Note, at fair value 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Helocyte Convertible Note, at fair value 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Helocyte Convertible Note, at fair value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Caelum Convertible Note, at fair value 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Caelum Convertible Note, at fair value 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Caelum Convertible Note, at fair value 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: Discount on notes payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note 1: – Classified as short-term on the Company’s Consolidated Balance Sheet as of December 31, 2018.
Note 2: – Classified as short-term on the Company’s Consolidated Balance Sheet as of December 31, 2017.
Note 3: – Classified as short-term on the Company’s Consolidated Balance Sheet as of December 31, 2018 and 2017.
|
Schedule Of Interest Expenses For Debt Arrangements |
The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan:
|
|
For the Years Ended December 31, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IDB Note |
|
$ |
341 |
|
|
$ |
- |
|
|
$ |
341 |
|
|
$ |
340 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
340 |
|
NSC Debt |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
147 |
|
|
|
- |
|
|
|
201 |
|
|
|
348 |
|
2017 Subordinated Note Financing |
|
|
4,217 |
|
|
|
1,363 |
|
|
|
5,580 |
|
|
|
2,234 |
|
|
|
- |
|
|
|
686 |
|
|
|
2,920 |
|
Opus Credit Facility |
|
|
1,141 |
|
|
|
636 |
|
|
|
1,777 |
|
|
|
1,085 |
|
|
|
- |
|
|
|
1,037 |
|
|
|
2,122 |
|
Venture Debt |
|
|
1,364 |
|
|
|
420 |
|
|
|
1,784 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
LOC Fees |
|
|
30 |
|
|
|
- |
|
|
|
30 |
|
|
|
36 |
|
|
|
- |
|
|
|
- |
|
|
|
36 |
|
Helocyte Convertible Note |
|
|
94 |
|
|
|
- |
|
|
|
94 |
|
|
|
261 |
|
|
|
1 |
|
|
|
- |
|
|
|
262 |
|
Avenue Convertible Note |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
5 |
|
|
|
3 |
|
|
|
- |
|
|
|
8 |
|
Caelum Convertible Note |
|
|
787 |
|
|
|
- |
|
|
|
787 |
|
|
|
265 |
|
|
|
100 |
|
|
|
1,217 |
|
|
|
1,582 |
|
Falk CSR |
|
|
(64 |
) |
|
|
- |
|
|
|
(64 |
) |
|
|
64 |
|
|
|
- |
|
|
|
- |
|
|
|
64 |
|
Other |
|
|
11 |
|
|
|
- |
|
|
|
11 |
|
|
|
5 |
|
|
|
- |
|
|
|
- |
|
|
|
5 |
|
Total Interest Expense and Financing Fee |
|
$ |
7,921 |
|
|
$ |
2,419 |
|
|
$ |
10,340 |
|
|
$ |
4,442 |
|
|
$ |
104 |
|
|
$ |
3,141 |
|
|
$ |
7,687 |
|
Note 1: Amortization of fees
|